PTC Therapeutics Faces Setback on Translarna Approval

PTC Therapeutics ( (PTCT) ) has provided an announcement.

PTC Therapeutics announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has upheld its negative stance on renewing the conditional marketing authorization for Translarna, a treatment for Duchenne muscular dystrophy. Despite the committee’s decision, which contradicts the wishes of many European patients and physicians, PTC plans to ensure continued access and provide comprehensive evidence for the European Commission’s upcoming review.

For detailed information about PTCT stock, go to TipRanks’ Stock Analysis page.